VERTEX PHARMACEUTICALS INC (VRTX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for VRTX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| VRTX | Executive Chairman, Vertex | 70 | ["Chief Executive Officer and President of Vertex Pharmaceuticals Incorporated from 2012 through March 2020", "Chairman of Board of Directors of Vertex Pharmaceuticals Incorporated since 2012; previously served as lead independent director from 2010 through 2011", "Managing Director at Clarus Ventures, a life sciences venture capital firm, from 2006 to 2012", "President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group and a member of the board of directors of Abbott Laboratories from 2001 to 2006", "Held several academic appointments from 1987 to 2000, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago", "Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health", "Professor of Medicine at Harvard Medical School", "Elected member of the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences", "Member of the board of directors of Quest Diagnostics Incorporated from 2014 to May 2019", "Member of the board of directors and non-executive Vice Chairman of Shire plc from 2006 to 2012", "Chairman of Revolution Healthcare Acquisition Corp. from April 2021 to December 2022", "Holds M.D., Ph.D. and B.A. degrees from the University of Chicago"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Age: 70 Director Since: 2009 Position: Executive Chairman Experience: Other Public Company Boards: None Chief Executive Officer and President of Vertex Pharmaceuticals Incorporated from 2012 through March 2020 Chairman of Board of Directors of Vertex Pharmaceuticals Incorporated since 2012; previously served as lead independent director from 2010 through 2011 Managing Director at Clarus Ventures, a life sciences venture capital firm, from 2006 to 2012 President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group and a member of the board of directors of Abbott Laboratories from 2001 to 2006 Held several academic appointments from 1987 to 2000, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School Elected member of both the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences Member of the board of directors of Quest Diagnostics Incorporated, a publicly traded medical diagnostics company, from 2014 to May 2019; member of the board of directors and non-executive Vice Chairman of Shire plc, a specialty biopharmaceutical company, from 2006 to 2012; Chairman of Revolution Healthcare Acquisition Corp., a special purpose acquisition corporation, from April 2021 to December 2022 Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago Key Skills and Qualifications: Dr. Leiden possesses strong leadership qualities, demonstrated through his service as a senior executive in the biotechnology and pharmaceutical industries and as a life sciences venture capitalist. He has extensive knowledge of the science underlying drug discovery and development through his experiences as a distinguished physician, scientist, and teacher. As our former CEO and as a former senior executive at Abbott Laboratories, he brings a global perspective to our business and public policy issues facing our company. He also provides our board of directors with in-depth knowledge of our company and our corporate strategy.